Annual Accounts Payable
$33.12 M
+$6.52 M+24.51%
31 December 2023
Summary:
Iovance Biotherapeutics annual accounts payable is currently $33.12 million, with the most recent change of +$6.52 million (+24.51%) on 31 December 2023. During the last 3 years, it has risen by +$19.61 million (+145.12%). IOVA annual accounts payable is now at all-time high.IOVA Accounts Payable Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly Accounts Payable
$31.69 M
+$11.27 M+55.20%
30 September 2024
Summary:
Iovance Biotherapeutics quarterly accounts payable is currently $31.69 million, with the most recent change of +$11.27 million (+55.20%) on 30 September 2024. Over the past year, it has increased by +$12.41 million (+64.40%). IOVA quarterly accounts payable is now -4.34% below its all-time high of $33.12 million, reached on 31 December 2023.IOVA Quarterly Accounts Payable Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
IOVA Accounts Payable Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | +24.5% | +64.4% |
| 3 y3 years | +145.1% | +160.1% |
| 5 y5 years | +1109.3% | +219.4% |
IOVA Accounts Payable High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3 years | at high | +145.1% | -4.3% | +160.1% |
| 5 y | 5 years | at high | +1109.3% | -4.3% | +219.4% |
| alltime | all time | at high | -4.3% |
Iovance Biotherapeutics Accounts Payable History
| Date | Annual | Quarterly |
|---|---|---|
| Sept 2024 | - | $31.69 M(+55.2%) |
| June 2024 | - | $20.42 M(-20.6%) |
| Mar 2024 | - | $25.70 M(-22.4%) |
| Dec 2023 | $33.12 M(+24.5%) | $33.12 M(+71.9%) |
| Sept 2023 | - | $19.27 M(-38.1%) |
| June 2023 | - | $31.16 M(-1.3%) |
| Mar 2023 | - | $31.57 M(+18.7%) |
| Dec 2022 | $26.60 M(-2.8%) | $26.60 M(+9.7%) |
| Sept 2022 | - | $24.25 M(+21.2%) |
| June 2022 | - | $20.01 M(-2.2%) |
| Mar 2022 | - | $20.45 M(-25.3%) |
| Dec 2021 | $27.38 M(+102.6%) | $27.38 M(+124.8%) |
| Sept 2021 | - | $12.18 M(-44.4%) |
| June 2021 | - | $21.91 M(+63.9%) |
| Mar 2021 | - | $13.37 M(-1.1%) |
| Dec 2020 | $13.51 M(-13.2%) | $13.51 M(-45.5%) |
| Sept 2020 | - | $24.79 M(+142.2%) |
| June 2020 | - | $10.24 M(-3.5%) |
| Mar 2020 | - | $10.61 M(-31.8%) |
| Dec 2019 | $15.57 M(+468.3%) | $15.57 M(+56.9%) |
| Sept 2019 | - | $9.92 M(-22.4%) |
| June 2019 | - | $12.78 M(+68.4%) |
| Mar 2019 | - | $7.59 M(+177.1%) |
| Dec 2018 | $2.74 M(+122.3%) | $2.74 M(-54.5%) |
| Sept 2018 | - | $6.01 M(+15.7%) |
| June 2018 | - | $5.20 M(-21.0%) |
| Mar 2018 | - | $6.58 M(+433.8%) |
| Dec 2017 | $1.23 M | $1.23 M(-57.6%) |
| Sept 2017 | - | $2.90 M(-21.4%) |
| June 2017 | - | $3.69 M(+70.0%) |
| Date | Annual | Quarterly |
|---|---|---|
| Mar 2017 | - | $2.17 M(+151.9%) |
| Dec 2016 | $863.00 K(-9.9%) | $863.00 K(+278.5%) |
| Sept 2016 | - | $228.00 K(-68.6%) |
| June 2016 | - | $725.00 K(-31.2%) |
| Mar 2016 | - | $1.05 M(+10.0%) |
| Dec 2015 | $958.00 K(-23.2%) | $958.00 K(-17.5%) |
| Sept 2015 | - | $1.16 M(+0.4%) |
| June 2015 | - | $1.16 M(+4.5%) |
| Mar 2015 | - | $1.11 M(-11.3%) |
| Dec 2014 | $1.25 M(+202.2%) | $1.25 M(+117.5%) |
| Sept 2014 | - | $573.80 K(+30.3%) |
| June 2014 | - | $440.50 K(+53.9%) |
| Mar 2014 | - | $286.30 K(-30.7%) |
| Dec 2013 | $413.00 K(-62.4%) | $413.00 K(-73.4%) |
| Sept 2013 | - | $1.55 M(+4.7%) |
| June 2013 | - | $1.48 M(+14.6%) |
| Mar 2013 | - | $1.29 M(+17.6%) |
| Dec 2012 | $1.10 M(+478.1%) | $1.10 M(+30.5%) |
| Sept 2012 | - | $841.60 K(+38.1%) |
| June 2012 | - | $609.30 K(+20.8%) |
| Mar 2012 | - | $504.30 K(+165.4%) |
| Dec 2011 | $190.00 K(+527.1%) | $190.00 K(-8.2%) |
| Sept 2011 | - | $206.90 K(+58.4%) |
| June 2011 | - | $130.60 K(+80.1%) |
| Mar 2011 | - | $72.50 K(+139.3%) |
| Dec 2010 | $30.30 K(>+9900.0%) | $30.30 K(+18.8%) |
| Sept 2010 | - | $25.50 K(+61.4%) |
| June 2010 | - | $15.80 K(-7.6%) |
| Mar 2010 | - | $17.10 K(>+9900.0%) |
| Dec 2009 | $0.00 | $0.00(-100.0%) |
| June 2009 | - | $3800.00 |
FAQ
- What is Iovance Biotherapeutics annual accounts payable?
- What is the all time high annual accounts payable for Iovance Biotherapeutics?
- What is Iovance Biotherapeutics annual accounts payable year-on-year change?
- What is Iovance Biotherapeutics quarterly accounts payable?
- What is the all time high quarterly accounts payable for Iovance Biotherapeutics?
- What is Iovance Biotherapeutics quarterly accounts payable year-on-year change?
What is Iovance Biotherapeutics annual accounts payable?
The current annual accounts payable of IOVA is $33.12 M
What is the all time high annual accounts payable for Iovance Biotherapeutics?
Iovance Biotherapeutics all-time high annual accounts payable is $33.12 M
What is Iovance Biotherapeutics annual accounts payable year-on-year change?
Over the past year, IOVA annual accounts payable has changed by +$6.52 M (+24.51%)
What is Iovance Biotherapeutics quarterly accounts payable?
The current quarterly accounts payable of IOVA is $31.69 M
What is the all time high quarterly accounts payable for Iovance Biotherapeutics?
Iovance Biotherapeutics all-time high quarterly accounts payable is $33.12 M
What is Iovance Biotherapeutics quarterly accounts payable year-on-year change?
Over the past year, IOVA quarterly accounts payable has changed by +$12.41 M (+64.40%)